TrialClinical pharmacology and therapeutics2022

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

Ravi Shankar P Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.